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Abstract
Background and Objectives Hypertension is one of the
most common co-existing conditions in patients with
chronic pain, and the potential effects of an analgesic on
heart rate and blood pressure are of particular concern for
patients with hypertension. The purpose of this analysis
was to evaluate changes in blood pressure and heart rate
with tapentadol extended release (ER) treatment in patients
with hypertension.
Methods We performed a post hoc analysis of data pooled
from three randomized, placebo- and active-controlled,
phase III studies of tapentadol ER for managing chronic
osteoarthritis knee (NCT00421928, NCT00486811) or low
back (NCT00449176) pain (15-week, double-blind treatment
period). Data were independently analyzed for patients with a
listed medical history of hypertension at baseline and patients
with at least one listed concomitant antihypertensive medi-
cation at baseline. Heart rate, systolic blood pressure (SBP),
and diastolic blood pressure (DBP) were measured at each
visit.
Results In patients with a listed medical history of
hypertension (n = 1,464), least-squares mean (LSM
[standard error (SE)]) changes from baseline to endpoint
with placebo, tapentadol ER, and oxycodone HCl
controlled release (CR), respectively, were -0.7 (0.44), 0.2
(0.43), and -0.9 (0.45) beats per minute (bpm) for heart
rate; -2.4 (0.64), -2.7 (0.64), and -3.7 (0.67) mmHg for
SBP; and -1.0 (0.39), -1.3 (0.39), and -2.3 (0.41) mmHg
for DBP; in patients with at least one listed concomitant
antihypertensive medication (n = 1,376), the LSM (SE)
changes from baseline to endpoint were -0.6 (0.45), 0.1
(0.44), and -0.7 (0.47) bpm for heart rate; -1.8 (0.66),
-3.3 (0.65), and -3.7 (0.69) mmHg for SBP; and -0.7
(0.40), -1.4 (0.40), and -2.3 (0.42) mmHg for DBP.
Conclusion No clinically meaningful mean changes in
heart rate or blood pressure were observed for the evalu-
ated cohorts of patients with hypertension who were treated
with tapentadol ER (100–250 mg twice daily).
Key Points
Mean heart rate, systolic blood pressure, and
diastolic blood pressure values remained generally
unchanged over 15 weeks of treatment with placebo,
tapentadol extended release (ER; 100–250 mg twice
daily), or oxycodone HCl controlled release
(20–50 mg twice daily) in two patient cohorts:
patients with a listed medical history of hypertension
at baseline and patients with at least one listed
concomitant antihypertensive medication at baseline
Findings suggest that tapentadol ER is a reasonable
option when considering treatments for the
management of chronic pain in patients with
hypertension, although a personalized assessment of
patient risk and prudent clinical judgment are
recommended
ClinicalTrial.gov Identifiers: NCT00421928, NCT00486811, and
NCT00449176.
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1 Introduction
Hypertension is one of the most common co-existing
medical conditions in patients with chronic pain [1, 2]. In a
study of 29,132 patients with osteoarthritis [1], hyperten-
sion was the most common co-existing condition (52 % of
patients). Acetaminophen (paracetamol), NSAIDs, and
cyclo-oxygenase (COX)-2 inhibitors are often recom-
mended for patients initiating pharmacological therapy for
the management of osteoarthritis [3–5] and low back pain
[3, 6, 7]; however, use of acetaminophen [8], NSAIDs [9],
and COX-2 inhibitors [10] has been associated with
increases in blood pressure, which may be particularly
problematic for patients with pre-existing hypertension [3,
8, 9].
Serotonin norepinephrine reuptake inhibitors (SNRIs)
are often prescribed for the management of chronic mus-
culoskeletal pain, including chronic osteoarthritis pain and
chronic low back pain [11]. SNRIs have been associated
with increases in blood pressure and heart rate [12], pos-
sibly related to the norepinephrine reuptake inhibitor
component of their pharmacologic activity [13]. An
extended-release (ER) formulation of the centrally acting
analgesic tapentadol, which has both l-opioid receptor
agonist and norepinephrine reuptake inhibitor activities
[14–16], has demonstrated efficacy and safety for the
management of moderate to severe, chronic pain in adults
when a continuous, around-the-clock opioid analgesic was
needed for an extended period of time [17]. Phase III
clinical trials of tapentadol ER included studies in patients
with moderate to severe, chronic osteoarthritis hip or knee
pain [18, 19], low back pain [19, 20], and pain related to
diabetic peripheral neuropathy [21].
A pooled analysis [22] of data from three randomized,
placebo- and active-controlled, phase III studies with
15 weeks of double-blind treatment (two studies in chronic
osteoarthritis knee pain [18], one study in chronic low back
pain [20]) demonstrated that the efficacy of tapentadol ER
(100–250 mg twice daily) was non-inferior to that of
oxycodone HCl controlled release (CR; 20–50 mg twice
daily) for the management of moderate to severe, chronic
pain. In that analysis [22], the incidences of constipation,
nausea, vomiting, and the composite of nausea and/or
vomiting were significantly lower with tapentadol ER than
with oxycodone CR. An analysis of data pooled from the
same three studies demonstrated that tapentadol ER
(100–250 mg twice daily) treatment (n = 920) was not
associated with clinically meaningful changes in mean vital
sign measures, including heart rate and blood pressure [23].
The current post hoc pooled data analysis used data from
those three studies to evaluate changes in blood pressure
and heart rate in patients with a listed medical history of
hypertension or at least one listed concomitant antihyper-




Data were pooled from patients with a listed medical his-
tory of hypertension or at least one listed concomitant
antihypertensive medication at baseline who had partici-
pated in one of three double-blind, placebo- and active-
controlled, phase III studies of tapentadol ER for moderate
to severe, chronic osteoarthritis knee pain (Clinical-
Trials.gov Identifiers: NCT00421928 [18] or NCT00486811)
or low back pain (NCT00449176 [20]). Similar eligibility
criteria were used in all three studies; these criteria have
been described previously [22]. Patients with uncontrolled
hypertension were not permitted to participate in any of the
three studies.
Patients were not permitted to use antipsychotics, anti-
convulsants, antiparkinsonian medications, tricyclic anti-
depressants, or SNRIs within 14 days prior to screening or
during the study because the possible analgesic effects of
these medications could confound primary assessments of
analgesic efficacy. The use of monoamine oxidase inhibi-
tors was prohibited within 14 days prior to screening and
throughout the study. Systemic corticosteroids were not
permitted during the study or within 4 weeks of screening
for orally administered corticosteroids, 8 weeks for soft
tissue- or intramuscularly administered corticosteroids,
3 months for intra-articularly administered corticosteroids,
and 6 months for depot-injected corticosteroids.
2.2 Study Design
The three studies were conducted in accordance with the
ethical principles of the Declaration of Helsinki and Good
Clinical Practice. The protocols were reviewed and
approved by institutional review boards, and patients pro-
vided informed consent. The three studies included in this
analysis had similar designs, as outlined previously [22]
and briefly summarized here. Each randomized, double-
blind, multicenter, placebo- and active-controlled, phase III
study included a 15-week, double-blind treatment period
(3 weeks titration, 12 weeks maintenance). Patients were
randomized (1:1:1) to receive placebo, tapentadol ER, or
oxycodone CR. For the first 3 days of titration, patients
received twice-daily doses of placebo, tapentadol ER
50 mg, or oxycodone HCl CR 10 mg; active treatment
doses were then increased for the next 4 days to tapentadol
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ER 100 mg twice daily or oxycodone HCl CR 20 mg twice
daily (minimum therapeutic doses permitted to remain
eligible for treatment during the maintenance period in
these studies). Patients were then individually titrated to
the dose that provided the most favorable balance between
pain reduction and tolerability for the remaining 2 weeks
of titration. Under physician supervision, patients could
increase or decrease their doses of study medication by
50 mg twice daily for tapentadol ER or 10 mg twice daily
for oxycodone HCl CR within the prespecified therapeutic
ranges (tapentadol ER 100–250 mg twice daily; oxycodone
HCl CR 20–50 mg twice daily); doses could be increased
at a minimum of 3-day intervals or decreased with no time
restriction. Acetaminophen (B1,000 mg/day) was permit-
ted during titration except for the last 3 days. Although
patients made an effort to maintain steady dose concen-
trations of study medication throughout the maintenance
period, dose adjustments within the prespecified thera-
peutic ranges were permitted under physician supervision
to maintain the best possible balance of efficacy and
tolerability.
2.3 Study Evaluations and Statistical Analyses
Vital signs, including heart rate and supine or sitting blood
pressure, were recorded after patients had rested for 5 min
at each study visit in each study and were analyzed for all
randomized patients who had received one or more dose of
their study medication (safety population). For this post
hoc data analysis, heart rate, systolic blood pressure (SBP),
and diastolic blood pressure (DBP) were independently
analyzed for the following two cohorts: patients with a
listed medical history of hypertension at baseline and
patients with at least one listed concomitant antihyperten-
sive medication at baseline.
These analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC, USA). Descriptive
statistics were used to summarize absolute values and
changes from baseline to endpoint for heart rate and blood
pressure by treatment group. The baseline value was
defined as the last measured heart rate or blood pressure
value prior to the first dose of randomized treatment, and
the endpoint value was defined as the last measured, post-
baseline heart rate or blood pressure value during double-
blind treatment. Between-group differences in the least-
squares mean (LSM) change from baseline in heart rate and
blood pressure were evaluated using an analysis of
covariance (ANCOVA) model, with treatment, sex, base-
line body mass index group (\30 or C30 kg/m2), and study
as factors, and with age and baseline value as covariates.
The percentage of patients with changes from baseline
in heart rate in each of the following categories was eval-
uated by treatment group for each cohort: \0 beats per
minute (bpm), C0 to \10 bpm, C10 to \15 bpm, C15 to
\20 bpm, and C20 bpm. Similar evaluations were per-
formed to determine the percentages of patients with
changes from baseline in SBP or DBP of\0 mmHg, C0 to
\5 mmHg, C5 to \10 mmHg, C10 to \15 mmHg, and
C15 mmHg. The overall distributions of patients in the
categories of changes from baseline in heart rate, SBP, and
DBP were compared between the tapentadol ER and pla-
cebo groups, between the oxycodone CR and placebo
groups, and between the tapentadol ER and oxycodone CR
groups in each of the evaluated cohorts using the row mean
score option of the Cochran-Mantel-Haenszel test. The
percentages of patients with sustained (observed over three
or more consecutive visits) increases from baseline in SBP
or DBP of C5, C10, and C15 mmHg were also evaluated.
Treatment-emergent adverse events (TEAEs) were
recorded throughout the studies. Cardiovascular TEAEs
and serious cardiovascular TEAEs are summarized briefly.
3 Results
3.1 Patients
Data were analyzed for patients with a listed medical his-
tory of hypertension (n = 1,464) and patients with at least
one listed concomitant antihypertensive medication
(n = 1,376). In patients with a listed medical history of
hypertension, 86.9 % (1,272/1,464) also had at least one
listed concomitant antihypertensive medication. Demo-
graphic and baseline characteristics were generally com-
parable across treatment groups in both patient cohorts
(Table 1). The most commonly listed concomitant antihy-
pertensive medications (listed for C100 patients) were
lisinopril, ramipril, atenolol, metoprolol, and
hydrochlorothiazide.
3.2 Heart Rate
Mean heart rate values over time are summarized in Fig. 1.
Across both patient cohorts, there were no significant dif-
ferences in the LSM changes from baseline to endpoint in
heart rate between the tapentadol ER and placebo groups,
between the oxycodone CR and placebo groups, or
between the tapentadol ER and oxycodone CR groups.
LSM changes from baseline to endpoint in heart rate were
\1 bpm in both patient cohorts (Table 2).
The percentages of patients in each of the categories of
heart rate changes (\0, C0 to \10, C10 to \15, C15 to
\20, and C20 bpm) from baseline to endpoint in both
patient cohorts are summarized in Fig. 2. There were no
significant differences in the overall distribution of cate-
gories of heart rate changes from baseline to endpoint
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between the tapentadol ER and placebo groups or between
the tapentadol ER and oxycodone CR groups in either
cohort. For patients in both cohorts, a decrease was the
most commonly observed change in heart rate from base-
line to endpoint and was observed in similar percentages of
patients across all treatment groups (Fig. 2). In both patient
cohorts, the second most commonly observed change in
heart rate from baseline to endpoint across all treatment
groups was no change or an increase of\10 bpm (Fig. 2).
3.3 Systolic Blood Pressure
Mean SBP values over time are summarized in Fig. 3. LSM
changes from baseline to endpoint in SBP were not signifi-
cantly different between the tapentadol ER and placebo
groups or between the tapentadol ER and oxycodone CR
groups in either cohort. Significant differences were observed
in the LSM changes from baseline to endpoint in SBP
between the oxycodone CR and placebo groups in patients
with at least one listed concomitant antihypertensive
medication (p = 0.0442), but not in patients with a listed
medical history of hypertension (p = 0.1328). LSM changes
from baseline to endpoint in SBP were small (\4 mmHg)
across all treatment groups in both patient cohorts (Table 2).
The percentages of patients in each of the categories of SBP
changes (\0, C0 to \5, C5 to \10, C10 to \15, and
C15 mmHg) from baseline to endpoint are summarized in
Fig. 4. There were no significant differences in the overall
distribution of categories of SBP changes from baseline to
endpoint between the tapentadol ER and placebo groups or
between the tapentadol ER and oxycodone CR groups in either
patient cohort. The most common change in SBP from baseline
to endpoint was a decrease in all treatment groups for patients
in both cohorts; similar percentages of patients in the tapent-
adol ER and oxycodone CR treatment groups and a slightly
lower percentage of patients in the placebo group had a
decrease in SBP from baseline to endpoint (Fig. 4). The second
most commonly observed change in SBP was no change or an
increase of\5 mmHg (Fig. 4). In both patient cohorts, there
were no significant differences between the tapentadol ER and
Table 1 Baseline and demographic characteristics for patients with a listed medical history of hypertension and for patients with at least one
listed concomitant antihypertensive medication (safety population)














Mean (SD) [years] 61.6 (9.67) 61.3 (10.69) 60.9 (10.22) 62.1 (9.68) 61.0 (10.89) 61.2 (10.35)
Category [n (%)]a
\65 years 294 (61.6) 296 (60.7) 314 (62.9) 264 (59.2) 286 (62.0) 288 (61.4)
C65 to \75 years 141 (29.6) 136 (27.9) 131 (26.3) 139 (31.2) 127 (27.5) 129 (27.5)
C75 years 42 (8.8) 56 (11.5) 54 (10.8) 43 (9.6) 48 (10.4) 52 (11.1)
Sex [n (%)]
Male 162 (34.0) 158 (32.4) 189 (37.9) 161 (36.1) 155 (33.6) 178 (38.0)
Female 315 (66.0) 330 (67.6) 310 (62.1) 285 (63.9) 306 (66.4) 291 (62.0)
Race [n (%)]a
White 402 (84.3) 396 (81.1) 410 (82.2) 375 (84.1) 378 (82.0) 391 (83.4)
Black 51 (10.7) 68 (13.9) 54 (10.8) 45 (10.1) 62 (13.4) 45 (9.6)
Hispanic 12 (2.5) 15 (3.1) 21 (4.2) 15 (3.4) 14 (3.0) 21 (4.5)
Other 12 (2.5) 9 (1.8) 14 (2.8) 11 (2.5) 7 (1.5) 12 (2.6)
Baseline BMIb [kg/m2]
Mean (SD) 34.8 (8.28) 33.9 (8.03) 33.5 (6.92) 34.5 (8.17) 33.5 (7.86) 33.6 (7.06)
Baseline pain intensity scorec,d
Mean (SD) 7.3 (1.28) 7.4 (1.28) 7.3 (1.20) 7.3 (1.28) 7.4 (1.27) 7.3 (1.22)
BMI body mass index, CR controlled release, ER extended release, SD standard deviation
a Percentages may not total 100 % because of rounding
b History of hypertension: placebo, n = 474; tapentadol ER, n = 485; oxycodone CR, n = 495; listed concomitant antihypertensive medication:
placebo, n = 442; tapentadol ER, n = 458; oxycodone CR, n = 464
c History of hypertension: placebo, n = 475; tapentadol ER, n = 488; oxycodone CR, n = 499; listed concomitant antihypertensive medication:
placebo, n = 444; tapentadol ER, n = 461; oxycodone CR, n = 469
d Baseline pain intensity was defined as the average of available pain intensity scores (11-point numerical rating scale) during the last 72 h prior
to randomization
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placebo groups in the percentages of patients with sustained
(observed over three or more consecutive visits) increases in
SBP of C5, C10, or C15 mmHg (Table 3).
3.4 Diastolic Blood Pressure
Mean DBP values over time are summarized in Fig. 5. For
patients in both cohorts, LSM changes from baseline to
endpoint in DBP were small (\3 mmHg) across all treatment
groups (Table 2), and no significant differences were
observed in LSM changes from baseline to endpoint in DBP
between the tapentadol ER and placebo groups or between the
tapentadol ER and oxycodone CR groups. The differences in
the LSM changes from baseline to endpoint in DBP between
the oxycodone CR and placebo groups were significant in
patients with a listed medical history of hypertension
(p = 0.0159) and patients with at least one listed concomitant
antihypertensive medication (p = 0.0032).
The percentages of patients in each category of DBP
change (\0, C0 to \5, C5 to \10, C10 to \15, and
(a)
(b)
Fig. 1 Mean heart rate over
time for a patients with a listed
medical history of hypertension
and b patients with at least one
listed concomitant
antihypertensive medication
(safety population). BL baseline,
bpm beats per minute, CR
controlled release, ER extended
release
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C15 mmHg) from baseline to endpoint are summarized in
Fig. 6. There were no significant differences between the
tapentadol ER and placebo groups or between the tapent-
adol ER and oxycodone CR groups in the overall distri-
bution of categories of DBP changes from baseline to
endpoint in either patient cohort. Across all treatment
groups, the most commonly observed change in DBP from
baseline to endpoint was a decrease in DBP in both patient
cohorts; the percentage of patients with a decrease in DBP
from baseline to endpoint was comparable in the placebo
and tapentadol ER groups and slightly higher in the oxy-
codone CR group in both cohorts (Fig. 6). The second most
commonly observed change in DBP was in the category of
no change or an increase of C0 to \5 mmHg (Fig. 6). In
both cohorts, there were no significant differences between
the tapentadol ER and placebo groups in the percentages of
patients with sustained (observed over three or more
consecutive visits) increases in DBP of C5, C10, or
C15 mmHg (Table 3); however, in both cohorts, a signif-
icantly lower percentage of patients in the oxycodone CR
group than in the tapentadol ER group had sustained
increases in DBP of C5 mmHg (p \ 0.001 for both com-
parisons), but between-group differences in the percentages
of patients with sustained increases of C10 or C15 mmHg
were not significant (Table 3). Less than 4 % of patients in
any treatment group in both patient cohorts had sustained
increases from baseline in DBP of C15 mmHg (Table 3).
3.5 Cardiovascular Treatment-Emergent Adverse
Events
In patients with a listed medical history of hypertension,
cardiovascular TEAEs were reported in the placebo,
tapentadol ER, and oxycodone CR groups for 6.1 %
Fig. 2 Categories of heart rate
changes from baseline at
endpoint for patients with a
listed medical history of
hypertension and for patients
with at least one listed
concomitant antihypertensive
medication (safety population).
bpm beats per minute, CR
controlled release, ER extended
release
Table 2 Least squares mean (standard error) changes from baseline to endpoint in heart rate and blood pressure for patients with a listed medical
history of hypertension and for patients with at least one listed concomitant antihypertensive medication (safety population)













Heart rate (bpm) -0.7 (0.44) 0.2 (0.43) -0.9 (0.45) -0.6 (0.45) 0.1 (0.44) -0.7 (0.47)
SBP (mmHg) -2.4 (0.64) -2.7 (0.64) -3.7 (0.67) -1.8 (0.66) -3.3 (0.65) -3.7 (0.69)*
DBP (mmHg) -1.0 (0.39) -1.3 (0.39) -2.3 (0.41)** -0.7 (0.40) -1.4 (0.40) -2.3 (0.42)***
bpm beats per minute, CR controlled release, DBP diastolic blood pressure, ER extended release, SBP systolic blood pressure
* p = 0.0442, ** p = 0.0159, *** p = 0.0032 versus placebo
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(29/477), 8.6 % (42/488), and 11.2 % (56/499) of patients,
respectively. In patients with at least one listed concomi-
tant antihypertensive medication, cardiovascular TEAEs
were reported in the placebo, tapentadol ER, and oxyco-
done CR groups for 5.2 % (23/446), 8.5 % (39/461), and
11.9 % (56/469) of patients, respectively. The most com-
mon cardiovascular TEAEs (incidence C1 % in any
treatment group in either cohort) are summarized in
Table 4. A total of seven patients experienced serious
cardiovascular TEAEs; all seven patients were included in
both patient cohorts. One patient in the placebo group
experienced atrial fibrillation (considered serious and
unlikely to be related to study treatment). One patient in the
tapentadol ER group experienced atrial fibrillation (con-
sidered serious and possibly related to study treatment).
Five patients in the oxycodone CR group experienced
serious cardiovascular TEAEs (considered not related or
unlikely to be related to study treatment); two of these
patients experienced myocardial infarction, one experi-
enced angina pectoris and coronary artery occlusion, one




Fig. 3 Mean systolic blood
pressure over time for a patients
with a listed medical history of
hypertension and b patients with
at least one listed concomitant
antihypertensive medication
(safety population). BL baseline,
CR controlled release, ER
extended release, SBP systolic
blood pressure
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4 Discussion
This post hoc pooled analysis of data from three random-
ized, placebo- and active-controlled, phase III studies [18,
20] evaluated blood pressure and heart rate in patients with
a listed medical history of hypertension or at least one
listed concomitant antihypertensive medication at baseline
who were treated with tapentadol ER (100–250 mg twice
daily) for the management of chronic pain. Mean heart rate,
SBP, and DBP values remained generally unchanged over
15 weeks of treatment with placebo, tapentadol ER
(100–250 mg twice daily), or oxycodone HCl CR
(20–50 mg twice daily) in both patient cohorts. LSM
changes from baseline to endpoint in heart rate, SBP, and
DBP in all treatment groups were generally small and
negative for all three parameters in both patient cohorts. No
significant differences were observed between tapentadol
ER and placebo for any of the evaluated parameters. Based
on the categorical analyses of changes in heart rate, SBP,
and DBP, increases in these three parameters were
observed for approximately 45–55 % of patients in all
three treatment groups; however, results of these analyses
Fig. 4 Categories of systolic
blood pressure changes from
baseline at endpoint for patients
with a listed medical history of
hypertension and for patients
with at least one listed
concomitant antihypertensive
medication (safety population).
CR controlled release, ER
extended release
Table 3 Numbers and percentages of patients in each category of sustained systolic or diastolic blood pressure increase in the cohort of patients with a
listed medical history of hypertension and in the cohort of patients with at least one listed concomitant antihypertensive medication (safety population)a
Sustained increase
category [n (%)]














C5 mmHg 130 (28.3) 109 (23.6) 69 (16.7)* 121 (28.2) 105 (24.2) 64 (16.5)**
C10 mmHg 72 (15.7) 69 (14.9) 41 (9.9)* 69 (16.1) 65 (15.0) 37 (9.6)*
C15 mmHg 32 (7.0) 29 (6.3) 17 (4.1) 30 (7.0) 28 (6.5) 16 (4.1)
DBP
C5 mmHg 117 (25.5) 100 (21.6) 53 (12.8)*** 113 (26.3) 96 (22.1) 48 (12.4)***
C10 mmHg 56 (12.2) 45 (9.7) 33 (8.0) 50 (11.7) 44 (10.1) 26 (6.7)
C15 mmHg 17 (3.7) 15 (3.2) 7 (1.7) 13 (3.0) 15 (3.5) 7 (1.8)
CR controlled release, DBP diastolic blood pressure, ER extended release, SBP systolic blood pressure
* p \ 0.05, ** p \ 0.01, *** p \ 0.001 versus tapentadol ER
a A sustained increase was defined as an increase observed over C3 consecutive visits
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were generally comparable for the tapentadol ER and
placebo treatment groups. In patients with a listed history
of hypertension and in patients with at least one listed
concomitant antihypertensive medication, respectively,
decreases of 2.7 and 3.3 mmHg for SBP and 1.3 and
1.4 mmHg for DBP were observed after 15 weeks of
treatment with tapentadol ER (based on LSM changes from
baseline to endpoint).
The most commonly reported change in heart rate and
blood pressure in all treatment groups across both cohorts
was a decrease in heart rate or blood pressure, and only a
few patients experience a sustained (observed over three or
more consecutive visits) increase in SBP or DBP. Gener-
ally, decreases in DBP were observed for a higher per-
centage of patients in the oxycodone CR group than in the
placebo or tapentadol ER groups across both cohorts.
l-opioid receptor agonists have been associated with
decreases in blood pressure [24]; oxycodone is a pure
opioid agonist, while tapentadol also has norepinephrine
reuptake inhibitor activity, which may account for the
observed differences. The incidence of cardiovascular
TEAEs overall and the incidence of serious cardiovascular
(a)
(b)
Fig. 5 Mean diastolic blood
pressure over time for a patients
with a listed medical history of
hypertension and b patients with
at least one listed concomitant
antihypertensive medication
(safety population). BL baseline,
CR controlled release, DBP
diastolic blood pressure, ER
extended release
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TEAEs in the tapentadol ER group was low and similar to
incidences observed in the placebo group. These results are
consistent with previous observations from premarketing
analyses of data from ten phase II or III studies of
tapentadol ER showing that cardiac adverse drug reactions
(specifically heart rate increased, palpitations, heart rate
decreased, and left bundle branch block) were reported in
less than 1 % of patients taking tapentadol ER, while
vascular adverse drug reactions were reported in no more
than 2 % of patients (blood pressure decreased,\1 %; hot
flush, 2 %) [17].
Acetaminophen, NSAIDs, and COX-2 inhibitors are
generally considered to be the foundation of early treat-
ment options for chronic osteoarthritis pain [3–5] and low
back pain [3, 6, 7]. The use of these analgesics in patients
with a current or prior history of cardiovascular disease,
including hypertension, has been associated with increases
in blood pressure [8] (a risk factor for cardiovascular
events) and an increased risk for cardiovascular events
[4–6, 25, 26]. Significant increases in mean SBP (of up to
14.3 mmHg) and DBP (of up to 2.3 mmHg) have also been
observed with NSAIDs and COX-2 inhibitors in patients
with treated hypertension [9]. In the current study, no
significant increases in the LSM changes in SBP or DBP
were observed in the cohort of patients with a listed
medical history of hypertension or the cohort of patients
receiving at least one listed concomitant antihypertensive
medication in the tapentadol ER or oxycodone CR groups.
Fig. 6 Categories of diastolic
blood pressure changes from
baseline at endpoint for patients
with a listed medical history of
hypertension and for patients
with at least one listed
concomitant antihypertensive
medication (safety population).
CR controlled release, ER
extended release
Table 4 Cardiovascular treatment-emergent adverse events reported
for C1 % of patients in any treatment group in the cohort of patients
with a listed medical history of hypertension and in the cohort of
patients with at least one listed concomitant antihypertensive
medication (safety population)
System organ class
Preferred term [n (%)]













Any cardiovascular TEAE 29 (6.1) 42 (8.6) 56 (11.2) 23 (5.2) 39 (8.5) 56 (11.9)
Cardiac disorders 16 (3.4) 18 (3.7) 32 (6.4) 11 (2.5) 14 (3.0) 33 (7.0)
Palpitations 1 (0.2) 2 (0.4) 8 (1.6) 1 (0.2) 2 (0.4) 10 (2.1)
Angina pectoris 1 (0.2) 0 5 (1.0) 1 (0.2) 0 6 (1.3)
Vascular disorders 16 (3.4) 26 (5.3) 30 (6.0) 14 (3.1) 26 (5.6) 29 (6.2)
Hypertension 12 (2.5) 12 (2.5) 11 (2.2) 11 (2.5) 12 (2.6) 11 (2.3)
Hot flush 1 (0.2) 9 (1.8) 10 (2.0) 1 (0.2) 9 (2.0) 9 (1.9)
Flushing 1 (0.2) 1 (0.2) 4 (0.8) 1 (0.2) 1 (0.2) 5 (1.1)
CR controlled release, ER extended release, TEAE treatment-emergent adverse event
574 D. M. Biondi et al.
The retrospective post hoc design of this analysis and use
of data from patients involved in clinical trials may repre-
sent limitations for the interpretation and translation of
these results to clinical practice. In addition, the permitted
use of acetaminophen, which has previously been associ-
ated with an increase in blood pressure [8], as rescue
medication in the studies included in this pooled analysis
may have had an impact on these results; however, on
average, the number of days that patients received ace-
taminophen was low and similar across treatment groups,
and the percentage of patients receiving acetaminophen as
rescue medication was comparable across treatment groups.
Therefore, it is unlikely that the use of acetaminophen
would have had a clinically relevant impact on blood
pressure measures for this pooled patient population or on
blood pressure comparisons between treatment groups.
Furthermore, the use of b-blockers (b-adrenoceptor antag-
onists) as antihypertensive therapy may have had an impact
on results; however, the percentage of patients using
b-blockers at baseline was comparable across treatment
groups in the overall pooled patient population from these
three studies (placebo, 19.6 % [195/993]; tapentadol ER,
20.6 % [202/981]; oxycodone CR, 19.0 % [190/1,001]).
Therefore, it is unlikely that b-blocker use had an effect on
comparisons of blood pressure or heart rate between treat-
ment groups.
Results of the current post hoc analysis add to the body
of evidence associated with the cardiovascular safety
findings for tapentadol. These results are consistent with
those from a previous analysis of data pooled from the
same three studies, which showed no clinically meaningful
changes in mean vital sign measures, including heart rate
and blood pressure, in patients with chronic pain who were
receiving tapentadol ER (100–250 mg twice daily) treat-
ment [23]. Results of categorical analyses, which showed
increases in heart rate and blood pressure for some patients,
were generally similar for tapentadol ER and placebo.
Findings suggest that tapentadol ER is a reasonable option
when considering treatments for the management of
chronic pain in patients with hypertension, although a
personalized assessment of patient risk and prudent clinical
judgment are recommended.
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